Navigation Links
Stem Cell Study Shows Benefits in Treatment of Spinal Injuries
Date:11/10/2010

Stem Cell Study Shows Benefits in Treatment of Spinal Injuries -- SEOUL, South Korea, November 10, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

Stem Cell Study Shows Benefits in Treatment of Spinal Injuries

   

Results of 108 Patients Demonstrate Safety and Efficacy

SEOUL, South Korea, November 10, 2010 /PRNewswire/ -- Dr. Geeta Shroff, founder & medical director of Nutech Mediworld, presented today the summary results of a retrospective clinical study of human embryonic stem cell (hESC) therapy in patients with chronic spinal cord injury (SCI). Speaking at the 2nd Annual World Stem Cells & Regenerative Medicine Congress Asia 2010, Dr. Shroff explained her treatment protocol and clinical results, demonstrating the safety and efficacy of her human embryonic stem cell (hESC) therapy. The groundbreaking study was conducted on 108 chronic SCI patients treated by Dr. Shroff over a 6 year period-2004 to 2009. Dr Geeta Shroff also shared her vision, which is to see hESC therapy available globally as the first line of treatment for many of mankind's worst afflictions and her willingness to collaborate with entities and work with regulatory authorities worldwide, to realise this vision.

About the hESC Technology

Dr. Geeta Shroff has developed a commercially viable technology to isolate hESC, culture them, prepare them for clinical application and store them in ready-to-use form with a shelf life of six months. This technology, which has patents applied for worldwide, provides a safe and effective, 'purely human' product, for the treatment of a wide range of medical conditions. The ready-to-use product is universally acceptable as it does not require any cross- matching and has a shelf life of 6 months, making it amenable to global marketing. The technology is being used clinically to treat many conditions including spinal injuries, multiple sclerosis, Parkinson's disease, diabetes, Lyme disease, cerebral palsy and autism. Since 2002, more than 800 patients from 35 countries have been treated at Nutech Mediworld, New Delhi and the number is steadily growing.

For further information, please contact: Nutech Mediworld info@ntmw.net
'/>"/>

SOURCE Nutech Mediworld
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Study Shows Cardiovascular Deaths in Europe Could Be Prevented
2. Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD
3. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
4. Arizona State University awarded $6.5 million to study nanotechnology and society
5. Molecular Detections Detect-Ready™ MRSA Assay Demonstrates Strong Performance In Independent Comparative Study From Leading UK Hospital
6. Helix BioPharma Completes Definitive GLP Toxicology Studies With L-DOS47 and is Making Final Preparations for its Planned Phase I/II Clinical Study IND/CTA Submissions
7. Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 Diabetes
8. CoreLab Partners Completes First TQT Study in Japan
9. Kibow Biotech Releases Results of Pilot Scale Study of Its Probiotic Formulation for Kidney Health
10. ISTA Pharmaceuticals Highlights Clinical Data from REMURA™ Phase 2 Study Presented at the 6th International Conference on the Tear Film & Ocular Surface
11. Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... March 28, 2017 Biostage, Inc. ... developing bioengineered organ implants to treat cancers and other ... announced that Jim McGorry, CEO of Biostage, ... panel at the MassBio 2017 Annual Meeting ... ET in Cambrige, Massachussetts. The 3D Printing and ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... weigh modules. These weigh modules are designed according to European Hygienic Engineering ... , As fully integrated weighing solutions, SWB805 MultiMount weigh modules reduce contamination ...
(Date:3/27/2017)... , March 27, 2017 Roka Bioscience, Inc. (NASDAQ: ... solutions for the detection of foodborne pathogens,  today announced that ... & Company Spring 2017 Convention on March 29 at 9:50am ... Marriott Marquis. About Roka Bioscience ... Roka Bioscience ...
(Date:3/27/2017)... , March 27, 2017 Infectex Ltd., a Russian portfolio ... 2b-3 clinical study of SQ109 added to the standard drug therapy regimen in patients ... scientists at Sequella, Inc. ( USA ) and the US National Institutes ... ... Maxwell Biotech Venture Fund Logo ...
Breaking Biology Technology:
(Date:3/7/2017)... March 7, 2017 Brandwatch , the leading social ... The Prince,s Trust to uncover insights to support its reporting, ... The UK,s leading youth charity will be using Brandwatch ... and get a better understanding of the topics and issues that ... ...
(Date:3/2/2017)... Who risk to be deprived of its ... report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND SAMSUNG ... Fingerprint sensors using capacitive technology represent a fast growing ... forecasts an increase of 360% of the number of ... fingerprint sensor market between 2014 and 2017 (source : ...
(Date:2/28/2017)... BARCELONA , Spanien, 27. Februar 2017 /PRNewswire/ ... durch Iris-Scan, wird seine erstklassige biometrische Lösung ... Snapdragon™ 835 mit X16 LTE auf dem ... 2. März) am Qualcomm-Stand in Halle 3, ... 835-Prozessor beinhaltet die Sicherheitsplattform Qualcomm Haven™ – ...
Breaking Biology News(10 mins):